Exicure Inc. (XCUR): Rasio kapitalisasi marang pendapatan
Exicure, Inc. (XCUR) adheres to basic environmental standards, minimizing environmental impact within its laboratories. Management is currently restructuring the business in an effort to preserve intellectual capital for survival. The current P/S ratio reflects the price-to-sales valuation trend, where the metric is fixed at 70.90. Transitioning to a patent licensing model reduces R&D costs, establishing a foundation for stable cash flow.
Rincian analitis perusahaan Exicure, Inc. (XCUR)
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas Exicure, Inc.|XCUR - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas exicuretx.com|XCUR - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Exicure Corp|XCUR - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Exicure|Rasio likuiditas darurat exicuretx.com
- data bathi bisnis lan rasio investasi:
XCUR - Bathi resik perusahaan|Prakiraan bathi resik Exicure, Inc.|XCUR - Pangali P/E|Pangali Forward P/E exicuretx.com|XCUR - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Exicure Corp|XCUR - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Exicure|XCUR - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan exicuretx.com|XCUR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Exicure, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Ringkesan analitik perusahaan:XCUR Exicure Inc.
The P/S multiple determines the market value of each unit of generated revenue, reflecting the business valuation relative to its sales. By analyzing the average P/S of a company, an investor can observe capitalization dynamics linked to actual cash flow. High sensitivity of this indicator to price fluctuations signals a speculative nature of the valuation. For Exicure, Inc. (XCUR), this is critical, as asset restructuring and liquidity shortages amplify the volatility of this metric.
Pesaing Exicure, Inc.
Koefisien rega marang pendapatan Tempus AI|Rasio rega marang pendapatan Qiagen QGEN|IONS: Rasio kapitalisasi marang pendapatan|Repligen Corp. - Multiplikator P/S|Avidity Corp (RNA) - Kapitalisasi marang pendapatan|CRSP (CRISPR Therapeutics AG) - Kapitalisasi marang pendapatan|WGS - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan RARE|Rasio kapitalisasi marang pendapatan BEAM (Beam Therapeutics Inc)|Multiplikator P/S SRPT|Kapitalisasi marang pendapatan Twist Bioscience Corp TWST|10x Genomics, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S intelliatx.com NTLA|STOK - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan BLFS (BioLife Solutions Inc)|WVE: Multiplikator P/S|Rasio kapitalisasi marang pendapatan MAZE|Rasio rega marang pendapatan Sionna Therapeutics Inc|Rasio kapitalisasi marang pendapatan PRME (primemedicine.com)|Multiplikator P/S TSHA|Multiplikator P/S uniQure NV (QURE)|Multiplikator P/S MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Rega marang dodolan|SLDB: Kapitalisasi marang pendapatan|OCGN (ocugen.com) - Rasio kapitalisasi marang pendapatan|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|DSGN (Design Pharma) - Multiplikator P/S|Kapitalisasi marang pendapatan Rocket Corp (RCKT)|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics)|Multiplikator P/S lexeotx.com (LXEO)|Rasio rega marang pendapatan Korro Bio KRRO|Rasio kapitalisasi pasar marang pendapatan EDIT|Silence Therapeutics Inc. - Multiplikator P/S|Rega marang dodolan ProQR Therapeutics N.V.|CDXS (codexis.com) - Kapitalisasi marang pendapatan|sangamo.com - Rasio kapitalisasi pasar marang pendapatan|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator P/S|Metagenomi Inc. (MGX) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Precision BioSciences, Inc. (DTIL)|generationbio.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BOLD (Boundless Bio, Inc.)|IMNN - Kapitalisasi marang pendapatan|PHIO: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Mustang Bio, Inc. MBIO|RNAZ (transcodetherapeutics.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Sciences) - Multiplikator P/S|Kapitalisasi marang pendapatan bluebirdbio.com (BLUE)|Kapitalisasi marang pendapatan IPA (ImmunoPrecise Antibodies)|Multiplikator P/S Omega Therapeutics Inc (OMGA)|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals - Multiplikator P/S|TBIO (telesisbio.com) - Rasio kapitalisasi marang pendapatan|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan UBX
